SENS-401

Sensorion · Phase 2 active Small molecule

At a glance

Generic name	SENS-401
Sponsor	Sensorion
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease (PHASE2)
Evaluation of the Presence of SENS-401 in the Perilymph (PHASE2)
Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss (PHASE2, PHASE3)
A Study of SENS 401 in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SENS-401 CI brief — competitive landscape report
SENS-401 updates RSS · CI watch RSS
Sensorion portfolio CI